Privilège Ventures — 2022 Investments
3 investments dated 2022 · listed companies and verified rows first · show all
Adiposs develops ImageBAT, a contrast agent for medical imaging of brown fat that can identify patients at increased cancer risk and with higher treatment failure risk.
BiotechDigital HealthMedical Devices
Duc Tran(Chief Development Officer)
Co-investorsKickfund
Smeetz builds AI-powered software for the attractions industry, offering tools such as dynamic pricing to optimise operations, capacity, and guest experiences.
AI & Machine LearningFintechRetail TechSaaSTravel & Hospitality
Alexandre Martin(Founder)in
Co-investorsSICTIC
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
TYXIT
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.




